BPC-157

1. 01Gut

   Origin in stomach juice, first tested on the gut

   BPC-157 copies a piece of a protein that was first found in human stomach juice. Early studies in rats tested whether it could protect the stomach, gut and liver from damage.

   For experts

   BPC-157 is described as a 15-residue fragment of a larger gastric-juice protein (body protection compound), first characterised in Croatia in the early 1990s. The earliest work is in rodents: it reduced stomach and small-intestine lesions after high-dose NSAIDs by over 75% by macroscopic size, and it improved healing of surgically made colonic fistulas in rats. FDA reviewers noted that no dose-response relationship was found in these studies and that the fistula and NSAID-lesion studies did not report tissue histology. It was not found to change gastric acid secretion or gut motility.[src][src]

2. 02Bloodstream

   Broken down within minutes in the blood

   Once in the blood, the body chops BPC-157 up very quickly. In rats and dogs, most of it was gone within about half an hour. It is turned into tiny pieces and then ordinary amino acids that the body reuses. Nobody has measured this in people.

   For experts

   After IV dosing the elimination half-life is 5.3 minutes in beagle dogs and 15.2 minutes in rats; exposure is linear across intramuscular doses, with intramuscular bioavailability of about 14-19% in rats and 45-51% in dogs. Tritium-labelled peptide was rapidly cleaved into small peptide fragments and single amino acids that enter normal amino-acid metabolism, with excretion mainly in urine and bile. Human pharmacokinetics are unreported; FDA notes that it does not appear to be absorbed systemically after a rectal enema.[src][src]

3. 03Bloodstream

   Signals linked to new blood vessel growth

   In cells and in rats, BPC-157 made blood vessels grow and blood flow return faster after a blocked leg artery. This is one of the main ideas for how it could help healing. It has not been shown to do this in people.

   For experts

   In the chick chorioallantoic membrane assay, the endothelial tube-formation assay and rat hind-limb ischaemia, BPC 157 increased vessel density and accelerated blood-flow recovery. In human endothelial cells it raised VEGFR2 expression (not VEGF-A), promoted VEGFR2 internalisation and time-dependently activated VEGFR2-Akt-eNOS signalling; blocking endocytosis with dynasore suppressed these effects. The study did not show that BPC 157 binds VEGFR2 directly.[src][src]

4. 04Heart

   Relaxing artery walls through nitric oxide

   In one lab study, small rings of artery taken from people having heart bypass surgery relaxed when BPC-157 was added. The effect was bigger when the artery lining was intact and was reduced when nitric oxide was blocked. This is lab tissue, not a treatment in a living person.

   For experts

   In residual internal mammary artery rings from 12 coronary bypass patients, BPC 157 produced concentration-dependent relaxation of phenylephrine-contracted rings, greater in endothelium-intact rings, and the effect was attenuated by the NOS inhibitor L-NAME, pointing to an endothelium-dependent nitric oxide pathway with residual NO-independent effects. This is ex vivo human tissue, not in vivo evidence. FDA reviewers list stimulation of nitric oxide synthesis among researchers' hypotheses from rodent work, but note that the mechanisms remain poorly understood.[src][src]

5. 05Muscle

   Tendon cells move and survive better in the dish

   When tendon cells from rats were grown in a dish with BPC-157, they crept outward faster, survived stress better and had more receptors for growth hormone. This fits the idea of faster tendon healing, but it comes from rat cells and rat injuries.

   For experts

   In rat Achilles tendon explants and fibroblasts, BPC 157 accelerated outgrowth, increased cell survival under H2O2 stress and dose-dependently increased migration, with increased phosphorylation of FAK and paxillin; it did not directly increase proliferation. A separate cDNA microarray study found growth hormone receptor among the most up-regulated genes, with JAK2 activation on adding growth hormone. A systematic review of the musculoskeletal literature (35 preclinical studies) reports improved functional and biomechanical outcomes in tendon, ligament, muscle and bone injury models, all of it animal data.[src][src][src]

6. 06Liver

   Protecting the liver in rat experiments

   In rats given liver-damaging chemicals, BPC-157 given before or with the chemical was reported to keep the liver healthier. No one has tested this in people, and it is unknown whether it helps once damage has already happened.

   For experts

   In rat models (bile duct and hepatic artery ligation, restraint stress, carbon tetrachloride, repeated diclofenac), BPC-157 given orally or intraperitoneally reduced liver necrosis and enzyme rises. FDA reviewers noted that the protective effect was similar at both tested doses (no dose-response), and that treatment after injury had not been tested in these models.[src]

7. 07Elsewhere

   What is still not known

   Scientists still do not know exactly what BPC-157 attaches to in the body. Many of the results come from a small number of research groups. Until careful human trials are done, its real effects in people are unknown.

   For experts

   FDA's 2026 evaluation states that molecular targets have not been identified, dose-response relationships have not been established for the reported gastrointestinal and hepatic effects, and the mechanisms remain poorly understood, which makes biological plausibility difficult to judge. A 2025 independent review describes the human evidence as three small pilot studies and says BPC-157 should be considered investigational.[src][src]

Around the world

Is BPC-157 legal where you live?

Related molecules